Coming of Age: CD96 Emerges as Modulator of Immune Responses

CD96 represents a type I transmembrane glycoprotein belonging to the immunoglobulin superfamily. CD96 is expressed mainly by cells of hematopoietic origin, in particular on T and NK cells. Upon interaction with CD155 present on target cells, CD96 was found to inhibit mouse NK cells, and absence of t...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology 2018-05, Vol.9, p.1072-1072
Main Authors: Georgiev, Hristo, Ravens, Inga, Papadogianni, Georgia, Bernhardt, Günter
Format: Article
Language:English
Subjects:
CD155
CD226
CD96
immunoglobulin superfamily
Immunology
NK cells
TIGIT
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c528t-49e8a7453500095400c59d85fa5b25ca5a5f065ce970b640d0a280fd100e0cd53
cites cdi_FETCH-LOGICAL-c528t-49e8a7453500095400c59d85fa5b25ca5a5f065ce970b640d0a280fd100e0cd53
container_end_page 1072
container_issue
container_start_page 1072
container_title Frontiers in immunology
container_volume 9
creator Georgiev, Hristo
Ravens, Inga
Papadogianni, Georgia
Bernhardt, Günter
description CD96 represents a type I transmembrane glycoprotein belonging to the immunoglobulin superfamily. CD96 is expressed mainly by cells of hematopoietic origin, in particular on T and NK cells. Upon interaction with CD155 present on target cells, CD96 was found to inhibit mouse NK cells, and absence of this interaction either by blocking with antibody or knockout of CD96 showed profound beneficial effects in containment of tumors and metastatic spread in murine model systems. However, our knowledge regarding CD96 functions remains fragmentary. In this review, we will discuss structural features of CD96 and their putative impact on function as well as some unresolved issues such as a potential activation that may be conferred by human but not mouse CD96. This is of importance for translation into human cancer therapy. We will also address CD96 activities in the context of the immune regulatory network that consists of CD155, CD96, CD226, and TIGIT.
doi_str_mv 10.3389/fimmu.2018.01072
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_9d02520a6fa7413ba4e23cacbfc62907</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_9d02520a6fa7413ba4e23cacbfc62907</doaj_id><sourcerecordid>2050485740</sourcerecordid><originalsourceid>FETCH-LOGICAL-c528t-49e8a7453500095400c59d85fa5b25ca5a5f065ce970b640d0a280fd100e0cd53</originalsourceid><addsrcrecordid>eNpVkc1r3DAQxUVpaEKSe07Fx152O9aXpVIKYZu2CymF0pzFWB65Dra1lexA__t6d9OQ6CIxevN7Dx5jVyWshTD2feiGYV5zKM0aSqj4K3ZWai1XgnP5-tn7lF3mfA_LkVYIod6wU26NNsD1Gfu4iUM3tkUMxXVLH4rNZ6uLm4FSS7nAXHyPzdzjFNNesV0MRyp-Ut7FMVO-YCcB-0yXj_c5u_ty82vzbXX74-t2c3278oqbaSUtGaykEmrJYJUE8Mo2RgVUNVceFaoAWnmyFdRaQgPIDYSmBCDwjRLnbHvkNhHv3S51A6a_LmLnDoOYWodp6nxPzjbAFQfUYXEsRY2SuPDo6-A1t1AtrE9H1m6uB2o8jVPC_gX05c_Y_XZtfHDKar1kXwDvHgEp_pkpT27osqe-x5HinB0HBdKo6iCFo9SnmHOi8GRTgtt36A4dun2H7tDhsvL2ebynhf-NiX9K-5Zl</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2050485740</pqid></control><display><type>article</type><title>Coming of Age: CD96 Emerges as Modulator of Immune Responses</title><source>PubMed Central</source><creator>Georgiev, Hristo ; Ravens, Inga ; Papadogianni, Georgia ; Bernhardt, Günter</creator><creatorcontrib>Georgiev, Hristo ; Ravens, Inga ; Papadogianni, Georgia ; Bernhardt, Günter</creatorcontrib><description>CD96 represents a type I transmembrane glycoprotein belonging to the immunoglobulin superfamily. CD96 is expressed mainly by cells of hematopoietic origin, in particular on T and NK cells. Upon interaction with CD155 present on target cells, CD96 was found to inhibit mouse NK cells, and absence of this interaction either by blocking with antibody or knockout of CD96 showed profound beneficial effects in containment of tumors and metastatic spread in murine model systems. However, our knowledge regarding CD96 functions remains fragmentary. In this review, we will discuss structural features of CD96 and their putative impact on function as well as some unresolved issues such as a potential activation that may be conferred by human but not mouse CD96. This is of importance for translation into human cancer therapy. We will also address CD96 activities in the context of the immune regulatory network that consists of CD155, CD96, CD226, and TIGIT.</description><identifier>ISSN: 1664-3224</identifier><identifier>EISSN: 1664-3224</identifier><identifier>DOI: 10.3389/fimmu.2018.01072</identifier><identifier>PMID: 29868026</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>CD155 ; CD226 ; CD96 ; immunoglobulin superfamily ; Immunology ; NK cells ; TIGIT</subject><ispartof>Frontiers in immunology, 2018-05, Vol.9, p.1072-1072</ispartof><rights>Copyright © 2018 Georgiev, Ravens, Papadogianni and Bernhardt. 2018 Georgiev, Ravens, Papadogianni and Bernhardt</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c528t-49e8a7453500095400c59d85fa5b25ca5a5f065ce970b640d0a280fd100e0cd53</citedby><cites>FETCH-LOGICAL-c528t-49e8a7453500095400c59d85fa5b25ca5a5f065ce970b640d0a280fd100e0cd53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5966540/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5966540/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53770,53772</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29868026$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Georgiev, Hristo</creatorcontrib><creatorcontrib>Ravens, Inga</creatorcontrib><creatorcontrib>Papadogianni, Georgia</creatorcontrib><creatorcontrib>Bernhardt, Günter</creatorcontrib><title>Coming of Age: CD96 Emerges as Modulator of Immune Responses</title><title>Frontiers in immunology</title><addtitle>Front Immunol</addtitle><description>CD96 represents a type I transmembrane glycoprotein belonging to the immunoglobulin superfamily. CD96 is expressed mainly by cells of hematopoietic origin, in particular on T and NK cells. Upon interaction with CD155 present on target cells, CD96 was found to inhibit mouse NK cells, and absence of this interaction either by blocking with antibody or knockout of CD96 showed profound beneficial effects in containment of tumors and metastatic spread in murine model systems. However, our knowledge regarding CD96 functions remains fragmentary. In this review, we will discuss structural features of CD96 and their putative impact on function as well as some unresolved issues such as a potential activation that may be conferred by human but not mouse CD96. This is of importance for translation into human cancer therapy. We will also address CD96 activities in the context of the immune regulatory network that consists of CD155, CD96, CD226, and TIGIT.</description><subject>CD155</subject><subject>CD226</subject><subject>CD96</subject><subject>immunoglobulin superfamily</subject><subject>Immunology</subject><subject>NK cells</subject><subject>TIGIT</subject><issn>1664-3224</issn><issn>1664-3224</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkc1r3DAQxUVpaEKSe07Fx152O9aXpVIKYZu2CymF0pzFWB65Dra1lexA__t6d9OQ6CIxevN7Dx5jVyWshTD2feiGYV5zKM0aSqj4K3ZWai1XgnP5-tn7lF3mfA_LkVYIod6wU26NNsD1Gfu4iUM3tkUMxXVLH4rNZ6uLm4FSS7nAXHyPzdzjFNNesV0MRyp-Ut7FMVO-YCcB-0yXj_c5u_ty82vzbXX74-t2c3278oqbaSUtGaykEmrJYJUE8Mo2RgVUNVceFaoAWnmyFdRaQgPIDYSmBCDwjRLnbHvkNhHv3S51A6a_LmLnDoOYWodp6nxPzjbAFQfUYXEsRY2SuPDo6-A1t1AtrE9H1m6uB2o8jVPC_gX05c_Y_XZtfHDKar1kXwDvHgEp_pkpT27osqe-x5HinB0HBdKo6iCFo9SnmHOi8GRTgtt36A4dun2H7tDhsvL2ebynhf-NiX9K-5Zl</recordid><startdate>20180517</startdate><enddate>20180517</enddate><creator>Georgiev, Hristo</creator><creator>Ravens, Inga</creator><creator>Papadogianni, Georgia</creator><creator>Bernhardt, Günter</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20180517</creationdate><title>Coming of Age: CD96 Emerges as Modulator of Immune Responses</title><author>Georgiev, Hristo ; Ravens, Inga ; Papadogianni, Georgia ; Bernhardt, Günter</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c528t-49e8a7453500095400c59d85fa5b25ca5a5f065ce970b640d0a280fd100e0cd53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>CD155</topic><topic>CD226</topic><topic>CD96</topic><topic>immunoglobulin superfamily</topic><topic>Immunology</topic><topic>NK cells</topic><topic>TIGIT</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Georgiev, Hristo</creatorcontrib><creatorcontrib>Ravens, Inga</creatorcontrib><creatorcontrib>Papadogianni, Georgia</creatorcontrib><creatorcontrib>Bernhardt, Günter</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Georgiev, Hristo</au><au>Ravens, Inga</au><au>Papadogianni, Georgia</au><au>Bernhardt, Günter</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Coming of Age: CD96 Emerges as Modulator of Immune Responses</atitle><jtitle>Frontiers in immunology</jtitle><addtitle>Front Immunol</addtitle><date>2018-05-17</date><risdate>2018</risdate><volume>9</volume><spage>1072</spage><epage>1072</epage><pages>1072-1072</pages><issn>1664-3224</issn><eissn>1664-3224</eissn><abstract>CD96 represents a type I transmembrane glycoprotein belonging to the immunoglobulin superfamily. CD96 is expressed mainly by cells of hematopoietic origin, in particular on T and NK cells. Upon interaction with CD155 present on target cells, CD96 was found to inhibit mouse NK cells, and absence of this interaction either by blocking with antibody or knockout of CD96 showed profound beneficial effects in containment of tumors and metastatic spread in murine model systems. However, our knowledge regarding CD96 functions remains fragmentary. In this review, we will discuss structural features of CD96 and their putative impact on function as well as some unresolved issues such as a potential activation that may be conferred by human but not mouse CD96. This is of importance for translation into human cancer therapy. We will also address CD96 activities in the context of the immune regulatory network that consists of CD155, CD96, CD226, and TIGIT.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>29868026</pmid><doi>10.3389/fimmu.2018.01072</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1664-3224
ispartof Frontiers in immunology, 2018-05, Vol.9, p.1072-1072
issn 1664-3224
1664-3224
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_9d02520a6fa7413ba4e23cacbfc62907
source PubMed Central
subjects CD155
CD226
CD96
immunoglobulin superfamily
Immunology
NK cells
TIGIT
title Coming of Age: CD96 Emerges as Modulator of Immune Responses
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T15%3A49%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Coming%20of%20Age:%20CD96%20Emerges%20as%20Modulator%20of%20Immune%20Responses&rft.jtitle=Frontiers%20in%20immunology&rft.au=Georgiev,%20Hristo&rft.date=2018-05-17&rft.volume=9&rft.spage=1072&rft.epage=1072&rft.pages=1072-1072&rft.issn=1664-3224&rft.eissn=1664-3224&rft_id=info:doi/10.3389/fimmu.2018.01072&rft_dat=%3Cproquest_doaj_%3E2050485740%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c528t-49e8a7453500095400c59d85fa5b25ca5a5f065ce970b640d0a280fd100e0cd53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2050485740&rft_id=info:pmid/29868026&rfr_iscdi=true